Evidence map›Paper›PMID 40295827›Full record

ArticleLeukemia2025

Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma.

Ioanna Xagoraris, Ying Yang, Erofili Bougka, Dora Trogrlic, Persa Xyderou, Konstantina Stathopoulou, Nikolas Herold, Andreas Lundqvist, George Z Rassidakis

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ioanna XagorarisDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Ying YangDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Erofili BougkaDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5970-8853
Dora TrogrlicDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Persa XyderouDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Konstantina StathopoulouDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Nikolas HeroldChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9468-4543
Andreas LundqvistDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-9709-2970
George Z RassidakisDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. georgios.rassidakis@ki.se.ORCID http://orcid.org/0000-0002-9082-4091

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2021-0113Cancerfonden (Swedish Cancer Society) 22 2205 PJRadiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet) 204133
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40295827
PMCPMC12208876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.